Seeking Alpha

SciClone Pharmaceuticals (SCLN) says it's entered into an agreement granting the company a...

SciClone Pharmaceuticals (SCLN) says it's entered into an agreement granting the company a license and the exclusive rights in China, Hong Kong and Macau to promote, market, distribute and sell Taiwan Liposome Company's ProFlow, a treatment for peripheral arterial disease and other indications. Under the terms of the agreement, Taiwan Liposome will be responsible for the continued development, clinical trials and manufacturing, and SCLN will be responsible for all aspects of commercialization, including pre- and post-launch activities.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs